Metoject (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate to its active form. This inhibition reduces the synthesis of nucleotides needed for DNA and RNA production, thereby slowing the growth of rapidly dividing cells in both immune-mediated conditions and malignant tumors.

The specific dose of Metoject is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and treatment goals. Dosage regimens vary widely across indications and should be individualized by a qualified healthcare professional.

Metoject is classified as Pregnancy Category X, indicating it is contraindicated in pregnancy due to a high risk of fetal harm. It is also not recommended while breastfeeding because methotrexate can be excreted in breast milk and may affect the infant.

To request Metoject, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Metoject (methotrexate) is a first‑line antimetabolite widely used for both autoimmune diseases and certain cancers. Compared with newer agents such as leflunomide or biologics, methotrexate offers a well‑established efficacy profile and lower cost, but it requires regular monitoring for toxicity and strict contraception measures.

Metoject must be stored at 2‑8 °C in a refrigerator, protected from light, and should never be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Metoject is supplied as a sterile injection and can be given intramuscularly, intravenously, or subcutaneously, depending on the clinical indication and physician preference. Administration is performed by a qualified healthcare professional in a controlled setting.

The most serious risks include bone marrow suppression leading to anemia, leukopenia, or thrombocytopenia; severe liver toxicity; pulmonary complications such as interstitial pneumonitis; and renal impairment. Patients should be monitored regularly for these adverse events.

Metoject is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe hepatic or renal impairment, and those receiving live vaccines. It should also be avoided in patients with uncontrolled infections or severe immunodeficiency.